Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apinocaltamide in photosensitive epilepsy
NCT03239691Phase 2Completed
- Sponsor
- Idorsia
- Start
- Oct 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of NBI-827104 in photosensitive epilepsy (PSE), sponsored by Idorsia. Started Oct 2017; status: completed.
02
Drugs
NBI-827104
03
Conditions
photosensitive epilepsy (PSE)
Beyond the preview
Go deeper on NCT03239691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03239691.